Arcturus Therapeutics Holdings Inc. (ARCT) AI Stock Analysis

Arcturus Therapeutics Holdings Inc. operates as an advanced-stage clinical biotechnology company specializing in mRNA medicines and vaccines. Founded in 2013 and headquartered in San Diego, California, the company utilizes proprietary technologies including LUNAR lipid-mediated delivery, STARR mRNA Technology (samRNA), and mRNA drug substance manufacturing. Its clinical pipeline includes vaccine and therapeutic programs for SARS-CoV-2 and Influenza. Through strategic partnerships, Arcturus is also advancing investigational therapies for ornithine transcarbamylase deficiency, cystic fibrosis, glycogen storage disease type III, and hepatitis B virus across platforms including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.

Arcturus reported annual revenue of $67.2M in FY2025, representing a revenue decline of 51.4% following $138.4M in FY2024 and $157.7M in FY2023. Over the 5-year period from FY2020 to FY2025, revenue grew at a CAGR of 47.8%. In FY2025, operating margin was -111.5% and net income was -$65.8M, with diluted EPS of -$2.38 and R&D expense of $112.2M. For the latest quarter ended June 30, 2026, quarterly revenue fell 89.5% year-over-year, while trailing twelve-month revenue totaled $29.4M with an operating margin of -863.3% and EPS of -$3.33.

As of June 30, 2026, Arcturus held $191.5M in cash and short-term investments against total debt of $22.9M, leaving net cash of $168.6M. The company reported a current ratio of 5.88 and a debt-to-equity ratio of 0.13, supported by shareholders' equity of $171.8M and total assets of $224.3M. In FY2025, operating cash flow was -$74.3M and free cash flow was -$74.3M. Capital expenditures totaled $230,000 for FY2025, while total shares outstanding grew 7.8% over the past 5 years.

Arcturus trades at an enterprise value of $209.8M and a market capitalization of $293.9M. Its forward P/E is 2.5x, compared to a median of 17.3x for its US-listed Healthcare peers. The company has a price-to-sales multiple of 10.0x and an EV-to-revenue ratio of 11.2x, relative to the peer median price-to-sales ratio of 4.1x. Over the past 12 months, the stock fell 52.4%, underperforming the S&P 500 (SPY) gain of 16.8%. However, ARCT is up 68.7% year-to-date and trades 17.5% above its 200-day average.

Wall Street coverage includes 10 Strong Buy, 1 Buy, and 2 Hold ratings, with zero Sell or Strong Sell recommendations. The mean price target is $23.80, which is 130.2% above the last close of $10.34. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $18.6M and EPS of -$3.45. For the next fiscal year, 10 analysts estimate revenue will grow 54.5% to $28.8M with an EPS of -$3.70. Arcturus beat EPS estimates in 3 of the last 4 quarters, with next earnings scheduled for November 9, 2026.

This page is an AI-written research summary of Arcturus Therapeutics Holdings Inc. (ARCT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ARCT income statement, ARCT balance sheet, ARCT key metrics, ARCT analyst forecast, ARCT chart. See the ARCT stock overview for the latest quote and news.